4basebio PLC, a company that develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, has appointed Gabe Longoria as Chief Commercial Officer.

The appointment follows the completion of the Company’s £40 million investment announced on November 12, 2024, which marked a key milestone in its journey to deliver scalable, high-quality synthetic DNA solutions to the global market, addressing critical needs in the gene therapy and mRNA vaccine sectors.

Longoria’s expertise in scaling commercial operations will play a crucial role in ensuring the Company’s synthetic DNA products reach their full market potential and the Company is well-positioned to deliver on its growth and commercialization goals in 2025 and beyond.

Experience

Longoria joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. During his leadership, Longoria supported the company in achieving exceptional financial growth, doubling revenues over a three-year period and expanding its market share globally. His strategic approach to scaling operations and fostering key partnerships solidified Astrea’s position as a leader in biopharmaceutical manufacturing solutions. Longoria has over two decades of commercial leadership in the life sciences sector and expertise in driving revenue growth, market expansion, and strategic partnerships for companies.

Commenting on his new role, Longoria said: “I am incredibly excited to join 4basebio at such a transformative stage in its journey. The Company’s groundbreaking synthetic DNA technology has the potential to revolutionize the gene therapy and vaccine industries, and I am eager to help bring these innovative products to a global audience. Leveraging my experience in driving growth and building strong commercial teams, I look forward to contributing to 4basebio’s mission of advancing human health through cutting-edge biotechnologies.”